Shares of Sarepta Therapeutics (SRPT) surged approximately 47% in after-hours trading on NasdaqGS after the U.S. Food and Drug Administration recommended lifting the voluntary hold on the company's gene therapy, Elevidys, for ambulatory patients with Duchenne Muscular Dystrophy (DMD). Following an investigation into the recent death of an 8-year-old patient, the FDA concluded that the incident was not related to the gene therapy product itself.
The FDA said it will continue to work with the sponsor regarding non ambulatory patients, which remains subject to a voluntary hold, following two deaths.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.